Phase 1 Fatty Liver Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1
Effect of Insulin Lowering on Lipogenesis
ObesityInsulin ResistanceNon-Alcoholic Fatty Liver Disease+2 more
Columbia University25 enrolled1 locationNCT07403604
Recruiting
Phase 1
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseOverweight and Obesity+1 more
Columbia University32 enrolled1 locationNCT06354088
Recruiting
Phase 1
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Fatty Liver Disease
Novo Nordisk A/S60 enrolled1 locationNCT07214870
Recruiting
Phase 1Phase 2
Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease
Fatty Liver
Tanta University50 enrolled1 locationNCT07242222
Recruiting
Phase 1Phase 2
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Fatty Liver
Tanta University50 enrolled1 locationNCT07238985
Recruiting
Phase 1Phase 2
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
Steatohepatitis, NonalcoholicFatty Liver Disease
Sadat City University46 enrolled1 locationNCT06302049
Recruiting
Phase 1
An Adaptive Design Study for the Assessment of the Safety, Tolerability and Pharmacokinetics of RYI-018 after Single Dosing in Healthy Volunteers and Repeat Dosing in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease
Bird Rock Bio Inc84 enrolled3 locationsACTRN12617000133336
Completed
Phase 1
A Multiple Daily Oral Dose Study of DUR-928 in Healthy Volunteers
Treatment of Fatty Liver Disease
INC Research28 enrolled1 locationACTRN12615000267550
Completed
Phase 1
First-in-Human, Single Ascending Oral Dose Study of DV-928 in Healthy Volunteers
Treatment of Fatty Liver Disease
INC Research36 enrolled1 locationACTRN12614001022651